Prognostic Significance and Function of
            <i>MCM10</i>
            in Human Hepatocellular Carcinoma

Chen, Yi-Ru; Li, Yiting; Wang, Mei-Qian; Zhu, Shuchai

doi:10.2217/fon-2021-0225

Cited by 4 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For qRT-PCR, 2× SYBR Green qPCR Master Mix (EZBioscience) was used. The qRT-PCR reactions were performed on a CFX96 Touch Real-time PCR Detection System (Bio-Rad, CA, USA) ( 29 ). The following forward (F) and reverse (R) primers were used for amplification: IGFBP7, F 5'-CGA GCA AGG TCC TTC CAT AGT-3' and R 5'-GGT GTC GGG ATT CCG ATG AC-3'; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), F 5'-GTC TCC TCT GAC TTC AAC AGC G-3' and R 5'-ACC ACC CTG TTG CTG TAG CCA A-3'.…”

Section: Methodsmentioning

confidence: 99%

Analysis of IGFBP7 expression characteristics in pan-cancer and its clinical relevance to stomach adenocarcinoma

Xu,

Wang,

Zhu

2023

Transl Cancer Res

View full text Add to dashboard Cite

Background Insulin-like growth factor (IGF) binding proteins (IGFBPs) are involved in tumorigenesis and cancer progression. IGFBP7 has been shown to act as either a tumor suppressive gene or an oncogene in many tumors, including stomach adenocarcinoma (STAD). To provide a more systematic and comprehensive understanding of IGFBP7 gene, we performed an integrative pan-cancer analysis and explored further with the case of STAD. Methods We compared the expression data of IGFBP7 in various cancer and normal tissues obtained from The Cancer Genome Atlas (TCGA) database and the Genotype-Tissue Expression (GTEx) database. The TISIDB web portal was used to analyze the associations of IGFBP7 with cancer molecular subtypes and immune subtypes. We also analyzed the predictive ability and prognostic values of IGFBP7 in pan-cancer, as well as explored its targeted binding proteins and their biological functions. Additionally, we examined the relationship between IGFBP7 and the clinical characteristics of STAD, investigated the co-expression genes and biological functions of differentially expressed genes (DEGs), and validated the mRNA and protein expression levels of IGFBP7 using gastric cancer (GC) and adjacent normal tissues in a small self-case-control study. Results IGFBP7 was found to be overexpressed in STAD and downregulated in many other cancers. The mRNA and protein expression levels of IGFBP7 were also significantly higher in the collected GC tissues compared with adjacent tissues. Expression of IGFBP7 varied significantly across molecular subtypes of nine different cancer types and immune subtypes of eight types, with the highest expression observed in the genomically stable molecular subtype and C3 inflammatory immune subtype in STAD. IGFBP7 demonstrated an area under the curve (AUC) >0.7 for predicting 16 cancer types, and an AUC >0.9 for seven types. Patients in the higher IGFBP7 expression group showed a poorer prognosis for adrenal cortical carcinoma (ACC) and low-grade glioma (LGG), while demonstrating a more favorable prognosis for kidney renal clear cell carcinoma (KIRC). IGFBP7 expression in STAD was significantly associated with T stage, pathological stage, histologic grade, and Helicobacter pylori infection. Conclusions IGFBP7 showed promise as a biomarker for prediction and prognosis in pan-cancer. IGFBP7 was found to be overexpressed in STAD, and its expression was closely associated with the clinical characteristics of STAD.

show abstract

Section: Methodsmentioning

confidence: 99%

Analysis of IGFBP7 expression characteristics in pan-cancer and its clinical relevance to stomach adenocarcinoma

Xu,

Wang,

Zhu

2023

Transl Cancer Res

View full text Add to dashboard Cite

show abstract

“…[311][312][313] MCM9 and MCM10 are associated with additional tumor types such as colorectal cancer, breast cancer, ovarian cancer, and HCC (Table 3). [314][315][316][317][318][319][320][321][322] Compared with the common-used proliferation biomarker, MCM proteins are more sensitive and particular than PCNA and Ki-67, 323 accurately reflecting cell proliferation status and predicting prognostic tumor patient's survival rate.…”

Section: Mcms As Diagnostic and Prognostic Biomarkersmentioning

confidence: 99%

“… 311 , 312 , 313 MCM9 and MCM10 are associated with additional tumor types such as colorectal cancer, breast cancer, ovarian cancer, and HCC (Table 3 ). 314 , 315 , 316 , 317 , 318 , 319 , 320 , 321 , 322 …”

Section: Dna Replication Disease and Therapymentioning

confidence: 99%

DNA replication: Mechanisms and therapeutic interventions for diseases

Song

Shen

Mahasin

et al. 2023

MedComm

View full text Add to dashboard Cite

Accurate and integral cellular DNA replication is modulated by multiple replication-associated proteins, which is fundamental to preserve genome stability. Furthermore, replication proteins cooperate with multiple DNA damage factors to deal with replication stress through mechanisms beyond their role in replication. Cancer cells with chronic replication stress exhibit aberrant DNA replication and DNA damage response, providing an exploitable therapeutic target in tumors. Numerous evidence has indicated that posttranslational modifications (PTMs) of replication proteins present distinct functions in DNA replication and respond to replication stress. In addition, abundant replication proteins are involved in tumorigenesis and development, which act as diagnostic and prognostic biomarkers in some tumors, implying these proteins act as therapeutic targets in clinical. Replication-target cancer therapy emerges as the times require. In this context, we outline the current investigation of the DNA replication mechanism, and simultaneously enumerate the aberrant expression of replication proteins as hallmark for various diseases, revealing their therapeutic potential for target therapy. Meanwhile, we also discuss current observations that the novel PTM of replication proteins in response to replication stress, which seems to be a promising strategy to eliminate diseases.

show abstract

“…In particular, high-throughput sequencing data can be used to identify key biomarkers associated with HCC progression, and these specific gene expression signature can effectively predict the risk and prognosis of HCC, providing new options for treatment. [6,7] For example, Chen et al found that high expression of MCM10 was associated with poor prognosis of patients with HCC and Medicine was an independent prognostic indicator for HCC [8] ; Ma et al showed that high expression of H2AFY predicted poor prognosis in HCC patients [9] ; Huo et al revealed that CTNNB1 mutations-related metabolic prognostic markers could be used in clinical practice to determine the prognosis of individual with HCC. [10] Taken together, biomarkers are relatively simple and noninvasive approach to detect and estimate disease prognosis, and will help physicians to better monitor patient outcomes and improve overall survival.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of LRRC1 in hepatocellular carcinoma and construction of relevant prognostic model

Cai¹,

Wu²,

Shen

et al. 2023

Medicine

View full text Add to dashboard Cite

This study aimed to elucidate the prognostic value of the leucine rich repeat containing 1 (LRRC1) gene in hepatocellular carcinoma (HCC) and to determine the effects of high and low LRRC1 expression on mutation and immune cell infiltration. We downloaded HCC mRNA-seq expression and clinical data from University of California Santa Cruz Xena. The expression of LRRC1 was compared between HCC tumor and normal samples. Tumor samples were divided according to high and low LRRC1 expression. Differentially expressed genes between the 2 groups were identified, and function, mutation, and immune cell infiltration were analyzed. Genes associated with immune cells were identified using weighted gene co-expression network analysis, and transcription factors of these genes were predicted. Moreover, a prognostic model was developed and its performance was evaluated. The expression of LRRC1 was upregulated in HCC tissues, and this indicated a poor prognosis for patients with HCC. Differentially expressed genes between high and low LRRC1 expression were significantly enriched in pathways associated with cancer, amino acid metabolism, carbohydrate metabolism, and the immune system. We identified 15 differentially infiltrated immune cells between tumors with high and low LRRC1 expression and 14 of them correlated with LRRC1 gene expression. Weighted gene co-expression network analysis identified 83 immune cell-related genes, 27 of which had prognostic value. Cyclic AMP-response element binding protein regulated annexin A5, matrix metallopeptidase 9, and LRRC1 in the transcription factor regulatory network. Finally, a prognostic model composed of 7 genes were generated, which could accurately predict the prognosis of HCC patients. The LRRC1 gene might serve as a potential immune-associated prognostic biomarker for HCC.

show abstract

Prognostic Significance and Function of MCM10 in Human Hepatocellular Carcinoma

Cited by 4 publications

References 46 publications

Analysis of IGFBP7 expression characteristics in pan-cancer and its clinical relevance to stomach adenocarcinoma

Analysis of IGFBP7 expression characteristics in pan-cancer and its clinical relevance to stomach adenocarcinoma

DNA replication: Mechanisms and therapeutic interventions for diseases

Prognostic significance of LRRC1 in hepatocellular carcinoma and construction of relevant prognostic model

Contact Info

Product

Resources

About